bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

[News]

bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.

More... (http://www.news-medical.net/news/20100305/bioTheranostics-launches-CancerTYPE-ID-database-and-KRAS-mutational-testing.aspx)